Abstract
P2X receptors are homo- or heterotrimeric ATP-gated cation channels that assemble from seven subunits, P2X1-P2X7. To our knowledge, no drug that acts on the P2X1 or P2X2 receptors in the CNS or elsewhere in the body has been approved, nor is there such a drug currently in clinical trials. Only a few non-drug-like antagonists such as the suramin derivatives NF449 and NF770 and the anthraquinone derivative PSB-1011 are available as pharmacological tools to block the P2X1 and P2X2 receptors, respectively. The focus of this review is twofold. First, we review the current knowledge of the role of the P2X1 and P2X2 receptors in normal and pathological CNS functions as inferred from experiments with wild-type, P2X1 knockout and P2X2 knockout mice. From the available data we conclude that the P2X1 and P2X2 receptors may have therapeutic potential as targets for neuroprotective drugs. Second, we review the impact of the recent resolution of the crystal structure of the zebrafish P2X4 receptor in the apo closed state and the ATP-bound open state. The P2X4 crystal structure opens the exciting possibility to generate P2X homology models for a rational drug design. In silico docking experiments with a homology-modeled rat P2X2 receptor revealed an almost perfect coordination of the nanomolar potent P2X2 antagonist NF770 through strong polar interactions between the acidic groups of NF770 and the mostly basic groups of the ATP-binding pocket. Such structural information might be helpful in designing drug-like compounds that function as selective P2X receptor antagonists without the pharmacokinetic limitations of the currently available antagonists.
Keywords: CNS injury, neuroprotection, antagonist binding, homology-modeling, in silico docking, PPADS, suramin, CNS injury, neuroprotection, antagonist binding, homology-modeling, in silico docking, PPADS, suramin, β-methylene-adenosine 5 -triphosphate, Zebrafish, Human P2X
CNS & Neurological Disorders - Drug Targets
Title:P2X1 and P2X2 Receptors in the Central Nervous System as Possible Drug Targets
Volume: 11 Issue: 6
Author(s): Ralf Hausmann and Gunther Schmalzing
Affiliation:
Keywords: CNS injury, neuroprotection, antagonist binding, homology-modeling, in silico docking, PPADS, suramin, CNS injury, neuroprotection, antagonist binding, homology-modeling, in silico docking, PPADS, suramin, β-methylene-adenosine 5 -triphosphate, Zebrafish, Human P2X
Abstract: P2X receptors are homo- or heterotrimeric ATP-gated cation channels that assemble from seven subunits, P2X1-P2X7. To our knowledge, no drug that acts on the P2X1 or P2X2 receptors in the CNS or elsewhere in the body has been approved, nor is there such a drug currently in clinical trials. Only a few non-drug-like antagonists such as the suramin derivatives NF449 and NF770 and the anthraquinone derivative PSB-1011 are available as pharmacological tools to block the P2X1 and P2X2 receptors, respectively. The focus of this review is twofold. First, we review the current knowledge of the role of the P2X1 and P2X2 receptors in normal and pathological CNS functions as inferred from experiments with wild-type, P2X1 knockout and P2X2 knockout mice. From the available data we conclude that the P2X1 and P2X2 receptors may have therapeutic potential as targets for neuroprotective drugs. Second, we review the impact of the recent resolution of the crystal structure of the zebrafish P2X4 receptor in the apo closed state and the ATP-bound open state. The P2X4 crystal structure opens the exciting possibility to generate P2X homology models for a rational drug design. In silico docking experiments with a homology-modeled rat P2X2 receptor revealed an almost perfect coordination of the nanomolar potent P2X2 antagonist NF770 through strong polar interactions between the acidic groups of NF770 and the mostly basic groups of the ATP-binding pocket. Such structural information might be helpful in designing drug-like compounds that function as selective P2X receptor antagonists without the pharmacokinetic limitations of the currently available antagonists.
Export Options
About this article
Cite this article as:
Hausmann Ralf and Schmalzing Gunther, P2X1 and P2X2 Receptors in the Central Nervous System as Possible Drug Targets, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581128
DOI https://dx.doi.org/10.2174/187152712803581128 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vivo Target Validation: Methodology and Case Studies on the Janus Kinase Tyk2
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Relaxin as a Cardiovascular Drug: A Promise Kept
Current Drug Safety Neurovascular Complications of Ovarian Hyperstimulation Syndrome (OHSS): From Pathophysiology to Recent Treatment Options
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Anti-Inflammatory Effects of C-Peptide Prevent Endothelial Dysfunction in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery Polyphenols: A Potential New Strategy for the Prevention and Treatment of Anxiety and Depression
Current Nutrition & Food Science Hydrogen Sulfide and Endothelial Dysfunction: Relationship with Nitric Oxide
Current Medicinal Chemistry From Rapid to Delayed and Remote Postconditioning: The Evolving Concept of Ischemic Postconditioning in Brain Ischemia
Current Drug Targets Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Microcirculatory Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions
Current Pediatric Reviews Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Interactions of Biologically Active Factors and Vascular Mediators During Hypertension in Pregnancy
Current Hypertension Reviews Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry